Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines

Area of Science:

• Hepatology
• Anesthesiology
• Immunology

Background:

• Halothane anesthesia is linked to liver dysfunction, presenting as two distinct types of hepatitis.
• Type I hepatitis involves minor liver function disturbances, while Type II is severe, potentially causing fulminant hepatic failure.
• Type II hepatitis is suspected to be an immune-mediated idiosyncratic reaction, though its exact mechanism remains unclear.

Purpose of the Study:

• To review the clinical presentation, immunological aspects, and prevention strategies for halothane-induced hepatitis.
• To differentiate between Type I and Type II halothane hepatitis and discuss their implications.

Main Methods:

• Review of existing literature on halothane hepatitis.
• Analysis of clinical, serological, and immunological features of halothane-induced liver injury.
• Examination of animal models investigating halothane's hepatotoxic potential.

Main Results:

• Halothane hepatitis occurs in two forms: Type I (mild, affecting 25-30% of patients) and Type II (rare, severe liver necrosis).
• Type II hepatitis exhibits characteristics of an immune-mediated reaction, with an incidence of 1 in 3500 to 35,000 procedures.
• Animal studies suggest direct hepatotoxicity of halothane, but its relevance to human reactions is uncertain.

Conclusions:

• Preventing halothane hepatitis is challenging; avoiding re-exposure in patients with prior adverse reactions (jaundice, pyrexia) is crucial.
• Patients with a family history of halothane sensitization should avoid the drug.
• Use of halothane-free equipment and avoidance of other volatile anesthetics are recommended in susceptible individuals.